Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

OBJECTIVES: The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte–macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSCLC) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jianjiao, Zhou, Yue, Wu, Lin, Ai, Xinghao, Dong, Xiaorong, Chu, Qian, Han, Chengbo, Wang, Xiaofei, Zhu, Zhengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444553/
https://www.ncbi.nlm.nih.gov/pubmed/34526044
http://dx.doi.org/10.1186/s13014-021-01905-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444553/
https://www.ncbi.nlm.nih.gov/pubmed/34526044
http://dx.doi.org/10.1186/s13014-021-01905-3

Ejemplares similares